Authors: Dovey, HF John, V Anderson, JP Chen, LZ Andrieu, PD Fang, LY Freedman, SB Folmer, B Goldbach, E Holsztynska, EJ Hu, KL Johnson-Wood, KL Kennedy, SL Kholedenko, D Knops, JE Latimer, LH Lee, M Liao, Z Lieberburg, IM Motter, RN Mutter, LC Nietz, J Quinn, KP Sacchi, KL Seubert, PA Shopp, GM Thorsett, ED Tung, JS Wu, J Yang, S Yin, CT Schenk, DB May, PC Altstiel, LD Bender, MH Boggs, LN Britton, TC Clemens, JC Czilli, DL Dieckman-McGinty, DK Droste, JJ Fuson, KS Gitter, BD Hyslop, PA Johnstone, EM Li, WY Little, SP Mabry, TE Miller, FD Ni, B Nissen, JS Porter, WJ Potts, BD Reel, JK Stephenson, D Su, Y Shipley, LA Whitesitt, CA Yin, T Audia, JE

Citation: Hf. Dovey et al., Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain, J NEUROCHEM, 76(1), 2001, pp. 173-181

Authors: Xu, YC Johnson, KW Phebus, LA Cohen, M Nelson, DL Schenck, K Walker, CD Fritz, JE Kaldor, SW LeTourneau, ME Murff, RE Zgombick, JM Calligaro, DO Audia, JE Schaus, JM

Citation: Yc. Xu et al., N-[3-(2-dimethylaminoethyl)-2-methyl-1H-indol-5-yl]-4-fluorobenzamide: A potent, selective, and orally active 5-HT1F receptor agonist potentially useful for migraine therapy, J MED CHEM, 44(24), 2001, pp. 4031-4034

Authors: McNulty, AM Audia, JE Bemis, KG Goode, RL Rocco, VP Neubauer, BL

Citation: Am. Mcnulty et al., Kinetic analysis of LY320236: competitive inhibitor of type I and non-competitive inhibitor of type II human steroid 5 alpha-reductase, J STEROID B, 72(1-2), 2000, pp. 13-21

Authors: Xu, YC Schaus, JM Walker, C Krushinski, J Adham, N Zgombick, JM Liang, SX Kohlman, DT Audia, JE

Citation: Yc. Xu et al., N-methyl-5-tert-butyltryptamine: A novel, highly potent 5-HT1D receptor agonist, J MED CHEM, 42(3), 1999, pp. 526-531